Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome

Conditions:   Recurrent Transformed Chronic Lymphocytic Leukemia;   Refractory Transformed Chronic Lymphocytic Leukemia;   Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma;   Recurrent Transformed B-Cell Non-Hodgkin Lymphoma;   Recurrent Transformed Non-Hodgkin Lymphoma;   Refractory Transformed Non-Hodgkin Lymphoma;   Refractory Transformed B-cell Non-Hodgkin Lymphoma;   Refractory Transformed Interventions:   Procedure: Biospecimen Collection;   Procedure: Bone Marrow Biopsy;   Procedure: Computed Tomography;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Procedure: Leukapheresis;   Biological: Lisocabtagene Maraleucel;   Procedure: Lymph Node Biopsy;   Procedure: Positron  Emission Tomography;   Drug: Zanubrutinib Sponsor:   Adam Kittai Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials